Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808261 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept (POC) in Patients With Ischaemic Stroke
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT01808261 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 134 participants.
The verdict
NCT01808261, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.
Interventions
- DRUG Placebo
- DRUG GSK249320 100/mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2013-05-18 |
| Est. Completion | 2014-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01808261
The ClinicalTrials.gov registry entry for NCT01808261 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01808261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01808261 about?
NCT01808261 is a clinical study titled "Proof of Concept (POC) in Patients With Ischaemic Stroke". Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.
What is the current status of trial NCT01808261?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2013-05-18. Estimated completion is 2014-07-28.
What interventions are being tested in trial NCT01808261?
The interventions under investigation include: Placebo (DRUG), GSK249320 100/mg (DRUG).
Who is sponsoring clinical trial NCT01808261?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.